Aggregability and Post-Transfusion Survival of Canine Platelets in Stored Whole Blood

Tsuchiya, Ryosuke; Yagura, H.; Hachiya, Yoshio; Mochizuki, Toshihiko; Furuichi, Mitsuru; Hisasue, Masaharu; Kobayashi, Kosaku; Yamada, Takatsugu

doi:10.1292/jvms.65.825

Cited by 9 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, frozen platelets in some preparations have significantly decreased activity 197,198 . Platelets in canine whole blood retain activity for up to 8 hours after collection when stored at room temperature 199 . Thus, whole blood transfusion may be a better solution to treat thrombocytopenia and/or platelet dysfunction in veterinary patients with trauma.…”

Section: Introductionmentioning

confidence: 99%

Fluid therapy for the traumatized patient

Driessen

Brainard

2006

J Vet Emergen Crit Care

View full text Add to dashboard Cite

Objective: To review the rationale behind and experiences with traditional and newly evolving concepts of fluid therapy in the traumatized patient, and to review conventional and novel fluid preparations for use in trauma resuscitation. Data sources: Human and veterinary clinical and research studies. Human data synthesis: Current treatment guidelines recommend aggressive fluid resuscitation with lactated ringers solution (LRS) or saline as optimum management of hemorrhagic shock in trauma, regardless of whether bleeding is controlled or not. The rationale behind this strategy is to restore intravascular volume as rapidly as possible to ensure adequate vital organ perfusion. Recently, this strategy has been challenged, especially in patients with uncontrolled hemorrhage, as neither laboratory evidence nor clinical trials support this practice. Current research indicates that vigorous fluid infusion may exacerbate bleeding and cause severe hemodilution, both impairing resuscitation outcome. As a result, a new line of thinking is emerging that balances the risks and benefits of intravenous volume infusion by offering the clinician alternative treatment strategies and emphasizes continuous endpoint‐oriented monitoring. ‘Hypotensive’ or ‘hypovolemic’ resuscitation techniques as well as initial volume replacement with fluids other than LRS or saline (e.g., hypertonic saline [HTS], HTS with dextran 70 [HTS‐D]) have been introduced in human medical practice as additional options for treatment of victims of trauma under certain circumstances. Clinical studies evaluating the use of hemoglobin‐based oxygen carriers (HBOCs) in the trauma setting are underway and may soon lead to an expansion of the fluid arsenal available to the clinician for treatment of trauma patients. Veterinary data synthesis: Based on available animal data, neither strict guidelines nor a clear fluid preference for resuscitation of traumatic shock have been defined. Although systematic clinical trials are missing, combinations of crystalloid and colloid (natural or artificial) appear to be as effective for resuscitation as crystalloid alone. Judicious use of an HBOC (e.g., Oxyglobin®) as a substitute for blood/red blood cells may be recommended in situations where whole blood or pRBCs are not or not yet available. Conclusions: The search for optimal methods of fluid resuscitation in trauma is ongoing. At this point the best solution is a differentiated approach to fluid therapy, one that tailors type and volume of resuscitation solution(s) used to the type and severity of injury in an individual patient and uses monitoring of perfusion and oxygenation parameters to guide resuscitation. Crystalloid fluids are effective for resuscitation but may need to be combined with or replaced by colloidal fluids in certain clinical situations.

show abstract

Section: Introductionmentioning

confidence: 99%

Fluid therapy for the traumatized patient

Driessen

Brainard

2006

J Vet Emergen Crit Care

View full text Add to dashboard Cite

show abstract

“… There are other preservatives, Adsol and Nutricel, for example, that can extend the storage of packed red blood cells for approximately 5 weeks, but the viability of platelets stored in whole blood for this extended amount of time has not been proven. One prospective study involving 18 dogs used FWB collected in CPDA1 to assess platelet aggregation with storage time and temperature, suggesting that canine platelets maintain viability when stored at room temperature for up to 8 hours in CPDA1 treated FWB . Once FWB is collected it should be stored at room temperature for a maximum of 8 hours and continuously rotated .…”

Section: Platelet Productsmentioning

confidence: 99%

“…One prospective study involving 18 dogs used FWB collected in CPDA1 to assess platelet aggregation with storage time and temperature, suggesting that canine platelets maintain viability when stored at room temperature for up to 8 hours in CPDA1 treated FWB . Once FWB is collected it should be stored at room temperature for a maximum of 8 hours and continuously rotated . However, Hughes et al performed a prospective study in which 10‐CPD whole blood units from human volunteers were collected and divided into 2 equal volumes, one‐half of each unit was then stored at 19°C (66.2°F) and the other half was stored at 25°C (77°F).…”

Section: Platelet Productsmentioning

confidence: 99%

Platelet transfusions: treatment options for hemorrhage secondary to thrombocytopenia

Hux

Martin²

2012

J Vet Emergen Crit Care

View full text Add to dashboard Cite

Objective To review current human and veterinary protocols for platelet transfusion triggers, available platelet transfusion products to support veterinary thrombocytopenic patients, and the advantages and disadvantages of each product. Data Sources Data from human and veterinary literature. Human Data Synthesis Prophylactic and therapeutic platelet transfusions are instrumental in managing human patients with thrombocytopenia. The platelet transfusion products used in human medicine consist of platelet concentrates, derived from pooled random donor platelets, or single‐donor apheresis platelets. Historically, platelet transfusions in human medicine have been prophylactic in nature; however, recent research suggests changing from a prophylactic transfusion strategy to a therapeutic transfusion strategy may be safe for most patients. The optimal platelet transfusion trigger and the use of prophylactic verses therapeutic platelet transfusions are ever changing in human medicine. Veterinary Data Synthesis There have been many advances in platelet transfusion products, but fresh whole blood remains the most commonly used platelet transfusion product in veterinary medicine. New products such as lyophilized platelets and cryopreserved platelets offer the benefits of long shelf life, immediate availability, and higher concentration of platelets at smaller doses. Veterinary platelet transfusion guidelines are mostly extrapolated from human literature because data on veterinary platelet transfusions are lacking. Conclusions In veterinary medicine the most commonly available product for platelet transfusions is fresh whole blood, because of availability of blood donors and lack of a cost effective easily obtainable alternative. Cryopreserved and lyophilized platelets are promising new products being used in the treatment of hemorrhaging patients with thrombocytopenia. These products offer increased platelet concentrations at decreased volumes, longer storage shelf life, and decreased exposure to whole blood products. With the development of newer readily available products, platelet transfusion parameters, to include dose, platelet count trigger, presence of disease, and clinical signs, should be further evaluated in veterinary medicine.

show abstract

“…The reason for this non-specific binding is not clear. In addition, most of the platelets were lost during the complicated preparation process, and it was concluded that positive platelets prepared by this chemical coupling method were not an appropriate positive control.IgM positive platelets were prepared by storage of EDTA-treated whole blood at 4C overnight as this has been reported to result in nonspecific binding of IgM to canine platelets [6,12]. Platelets strongly positive for IgG, IgM and C3 (IgG/IgM/C3 triple positive) were prepared by adding 5 mg/ml of lipopolysaccharide (LPS; from Escherichia Coli O127:B, Sigma-Aldrich Corporation, St. Louis, MO, U.S.A.) to citrated PRP and incubation at 37C for 30 min.…”

mentioning

confidence: 99%

“…The appropriate discrimination gate for platelets by forward-and side-light scatters was set as previously reported [12]. Background fluorescence was detected using negative control platelets similarly incubated with each of the FITC-conjugated antibodies described above.…”

mentioning

confidence: 99%

Preparation of Positive Control Platelets for Detection of Canine Platelet Surface-Associated IgG, IgM and Complement (C3) by Flow Cytometry

Tsuchiya

Komatsu

Ishikawa

et al. 2010

The Journal of Veterinary Medical Science

Self Cite

View full text Add to dashboard Cite

ABSTRACT. An assay for detection of platelet surface-associated (PSA-) IgG, IgM and/or complement (C3) in dogs was modified by preparation of artificial positive control platelets. Flow cytometry of fluorescein isothiocyanate (FITC)-conjugated anti-dog IgG, anti-dog IgM and anti-dog C3 antibodies was used to detect the PSA proteins. IgM single, IgM/C3 double and IgG/IgM/C3 triple positive platelets were prepared. FITC-conjugated anti-IgG antibody bound strongly only to the triple positive platelets. Binding of FITC-conjugated anti-IgM or anti-C3 antibody to the double and triple positive platelets was specifically blocked by preincubation with the respective non-FITC-conjugated same-origin antibodies. These results confirm that FITC-conjugated antibodies specifically detect PSA proteins and that the control platelets prepared in this study are appropriate positive controls for detection of PSA proteins by flow cytometry.KEY WORDS: canine, immune-mediated thrombocytopenia, platelet surface-associated immunological proteins, positive control.J. Vet. Med. Sci. 72(8): 1063-1066, 2010 Primary immune-mediated thrombocytopenia (IMTP) is a common disease in dogs. It is diagnosed clinically by exclusion of other diseases that may cause thrombocytopenia and response to immunosuppressive therapies including glucocorticoid administration. Direct measurement of PSA immunoglobulin (PSA-IgG and/or PSA-IgM) may be performed as a laboratory test to aid in confirmation of the diagnosis of IMTP [10]. In the direct anti-globulin test for canine primary immune-mediated hemolytic anemia (IMHA), not only IgG-and IgM-but also C3-bound erythrocytes are detected [1]. Therefore, it is possible that C3 may also be detected in primary canine IMTP. Complement may mediate adherence of immune complexes to the surface of platelets and may induce secondary IMTP in dogs because nonprimate platelets are presumed to have the complement factor 3b (C3b) receptor [3,8]. Therefore, detection of PSA-C3 may also be useful in diagnosis of canine IMTP.Methods used to detect PSA-IgG (and sometimes PSAIgM) include radioimmunoassay [11], flow cytometry [5,7,13] and single layer enzyme-linked immunosorbent assay [2,6]. For reliable detection of PSA-IgG, PSA-IgM and PSA-C3, preparations of positive and negative control platelets are essential. Although measurement of PSA protein on patient platelets should be evaluated objectively by comparison with a positive control in every assay, positive control platelets are not commercially available. Negative controls are prepared by using fresh platelets from healthy dogs. Previously, IgG positive control platelets have been prepared by incubating normal canine platelets in sera containing antiplatelet antibody. These anti-sera were obtained from either alloimmunized dogs [6,7], heteroimmunized rabbits [2] or dogs diagnosed with primary IMTP [11]. These sources required special efforts to obtain the sera, and furthermore, IgM positive and C3 positive controls were not used in these reports. In the present study, we des...

show abstract

Aggregability and Post-Transfusion Survival of Canine Platelets in Stored Whole Blood

Cited by 9 publications

References 16 publications

Fluid therapy for the traumatized patient

Fluid therapy for the traumatized patient

Platelet transfusions: treatment options for hemorrhage secondary to thrombocytopenia

Preparation of Positive Control Platelets for Detection of Canine Platelet Surface-Associated IgG, IgM and Complement (C3) by Flow Cytometry

Contact Info

Product

Resources

About